Back to Agenda
When is Real World Evidence Ready for Prime Time?
Session Chair(s)
Nancy Dreyer, MPH, FISPE
Founder, Dreyer Strategies LLC, United States
We see growing interest in the value of using real world data (RWD) to support label expansions and approvals of drugs for rare conditions and oncology products. The FDA released its Framework for Real World Evidence Program in December 2018, following release of the its MyStudies App designed to incorporate patient-originated data with other RWD for research purposes. In Europe, the Heads of Medicines Agencies and the European Medicines Agency released a joint report in February, 2019 on their big data taskforce summarizing many areas of interest to better understand RWD and its possible uses. We will distill key lessons from demonstration projects and other experience to understand what is being done to evaluate data sets to give confidence in a RW study design, and its findings, including the challenges encountered when comparing data from clinical trials with a medicine’s performance in routine clinical practice, as actually prescribed by physicians and taken by patients.
Learning Objective : Describe at least one innovative study design that used real world data for label expansion; Characterize the types of diseases and treatments for which real world evidence has been used to expand the labeled use.
Speaker(s)
Peter Stein, MD
Consultant, Peter Stein Consulting, LLC, United States
FDA Update
Tony Humphreys, MPharm
Head of the Regulatory Science and Innovation Task Force, European Medicines Agency, Netherlands
EMA Update
Gregory Daniel, PhD, MPH
Vice President, Head of Public Policy Innovation and Evidence, Eli Lilly and Company, United States
Panelist
Solomon Iyasu, DrMed, MPH
Principal, Iyasu Epi-RWE Strategy LLC , United States
Panelist
Have an account?